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Abstract (249 words) 
Background. Circulating Angiotensin Converting Enzyme 2 (ACE2) activity in chronic kidney 
disease (CKD) patients without previous history of cardiovascular disease (CVD) has been 
associated with classical risk factors (advanced age, diabetes and male gender). Furthermore, 
silent atherosclerosis has been described as a pathological link between CKD and CVD. We 
analyzed baseline ACE2 activity in non-dialysis CKD stages 3-5 (CKD3-5) patients as a 
biomarker of renal progression, silent atherosclerosis and cardiovascular events after 2 years of 
follow-up. 
Methods. Prospective study of 1458 CKD3-5 subjects without any previous cardiovascular 
event included in the Spanish multicenter NEFRONA study. Association between baseline 
circulating ACE2 activity and renal parameters, carotid/femoral echography, atheromatous 
disease, ankle brachial index, intima-media thickness, need of renal replacement therapy, 
cardiovascular events and mortality at 24 months of follow-up were analyzed. 
Results. Patients with an increase in the number of territories with plaques at 24 months 
showed significantly higher levels of baseline ACE2 activity as compared to stable patients 
(46.90±1.63 vs 38.73±1.59, p<0.001). Multivariate linear regression analysis showed that 
pathological ankle-brachial index and progressive silent atherosclerosis defined as an increased 
number of territories with plaques at 24 months were associated with increased baseline ACE2 
activity. Male gender, older age, diabetes and increased baseline circulating ACE2 activity were 
independent predictors of atherosclerosis at 24 months of follow-up. 
Conclusions. In CKD3-5 patients, higher circulating ACE2 activity at baseline is associated 
with higher risk for silent atherosclerosis, suggesting that ACE2 activity may serve as a 
biomarker to predict cardiovascular risk before CVD is established. 
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Introduction 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with 
chronic kidney disease (CKD) 1-3. The risk of death from any cause increases as the estimated 
GFR declines 2 and patients with end-stage renal disease (ESRD) have a rate of mortality that 
exceeds the need of renal replacement therapy 4. Silent atherosclerosis has been described as 
a pathological link between CKD and CVD and could be a useful marker for predicting adverse 
cardiovascular outcomes in CKD patients5, 6. In CKD patients, carotid intima media thickness 
(IMT) has been demonstrated to be increased as compared to healthy patients 7, 8 and to be an 
independent predictor of all-cause and cardiovascular mortality 9. In addition, carotid plaque 
largely increases the risk of CV events 10. Recent results from the multicenter prospective 
observational NEFRONA study 11, that includes CKD patients and controls without previous 
cardiovascular events, have shown that the prevalence of atheromatous plaques is higher 
among CKD patients, correlating with the severity of CKD. Interestingly, the highest prevalence 
is observed among dialysis patients 12, 13. 
The renin-angiotensin system (RAS) plays also a major role in the pathophysiology of CVD and 
renal injury14, 15. Within the RAS, angiotensin-converting enzyme 2 (ACE2) 16 acts as a 
monocarboxypeptidase that cleaves the C-terminal aminoacid of angiotensin II (AngII) to 
generate the peptide Ang1-7 which counteracts the adverse effects of AngII 17. ACE2 is an 
integral cell membrane protein that can undergo cleavage or shedding to release the 
catalytically active ectodomain into the circulation 18. Circulating ACE2 levels were at first only 
detected in subjects with advanced age and with higher prevalence of CVD, diabetes and 
hypertension 19. Subsequent studies have confirmed that circulating ACE2 activity can be 
detected in healthy subjects 20 and that it is increased in heart failure patients, acute myocardial 
infarction 21, 22, diabetes 23, kidney transplant patients 24, and in pre-dialysis CKD patients 25. We 
have recently shown that in CKD patients without previous history of CVD circulating ACE2 
activity directly correlates with the classical cardiovascular risk factors such as male gender, 
older age and diabetes 26. It has also been demonstrated a protective role of ACE2 against 
atherosclerosis in experimental studies. ACE2 overexpression has been shown to inhibit the 
development of early atherosclerotic lesions 27, 28 and to enhance the stability of atherosclerotic 
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plaques 29 partly due to counter regulation of AngII signaling and inhibition of inflammatory 
response. In concordance, ACE2 deletion increases the development of atherosclerosis in fat-
fed Ldlr−/− mice 30 and plaque accumulation in atherosclerosis-prone apolipoprotein E knockout 
(ApoE KO) mice 31. 
We have previously shown that circulating ACE2 activity in CKD patients without previous 
history of CVD from the NEFRONA study directly correlates with classical CV risk factors 
namely older age, diabetes and male gender26.  We now hypothesized that baseline ACE2 
activity in CKD stages 3-5 (CKD3-5) patients serves as a biomarker of renal progression, 
atherosclerosis and CV events after 24 months of follow-up. 
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1. Subjects and Methods 
1.1. Patients and Variables 
Study population included 1458 non-dialysis CKD3-5 subjects from the observational and 
multicenter study (NEFRONA project), recruited from October 2009 to June 2011 11, 26 and with  
24 months of follow-up. This prospective study included male and female patients without 
history of CVD (angina pectoris, acute myocardial infarction, ischemic stroke, hemorrhagic 
stroke, abdominal aortic aneurysm and atherosclerosis), and ages ranged between 18 and 74 
years old. Exclusion criteria were pregnancy, VIH infection, any type of organ transplantation, 
previous history of carotid artery disease, active infections, any hospitalization in the last month, 
and intercurrent illness that presumes absence of follow-up or survival expectation less than 1 
year. 
Baseline clinical variables, treatment profile, analytical variables, presence of plaques and 
ACE2 enzymatic activities have been previously reported 26, 32. For the prospective study at 24 
months, renal parameters (serum creatinine and glomerular filtration rate), carotid/femoral 
echography, atheromatous disease (AD), ankle brachial index (ABI), intima-media thickness 
(IMT), need of renal replacement therapy (kidney transplantation or dialysis), cardiovascular 
events and mortality were assessed (Figure 1).  
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Figure 1. Schematic representation of patients analyzed in the study.  For the analysis of 
renal parameters and subclinical atherosclerosis some patients were lost. Exclusion criteria 
during the 24 months of follow-up were patients in need of renal replacement therapy (dialysis 
or kidney transplant), all-cause of mortality, cardiovascular events, having an atheromatous 
disease at stage 3 (AD 3) or transfer to another hospital. 
 
1.2. Renal parameters 
Progression of renal disease was evaluated according to doubling of serum creatinine or 50% 
decrease in estimated glomerular filtration rate (eGFR) calculated with the modification of diet in 
renal disease (MDRD)-4 formula at 24 months. Renal replacement therapy was defined as 
kidney transplantation or dialysis during the 24 months of follow-up. For the assessment of 
doubling of serum creatinine and the decrease in eGFR, patients that started dialysis or had a 
kidney transplant during the 24 months of follow-up were excluded. 
1.3. Silent Atherosclerosis 
Subclinical atherosclerosis was evaluated as described previously 11. Participants underwent a 
carotid and femoral ultrasound to measure IMT, using the Vivid BT09 apparatus (General 
Electric instrument) equipped with a 6–13 MHz broadband linear array probe. The analysis of 
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the presence of atheromatous plaques was performed by a unique reader in a blinded fashion, 
using the semi-automatic software EchoPAC Dimension (General Electric Healthcare). To 
assess the quality of the reading and the intraobserver reliability, a sample of 20 individuals was 
measured 3–5 times on different days. A kappa coefficient of 1 was obtained, indicating 
excellent intraobserver reliability. 
Plaque presence was evaluated in a total of 10 territories: right common carotid arteries, right 
carotid bulb, right internal carotid arteries, left common carotid arteries, left carotid bulb, left 
internal carotid arteries, right common femoral arteries, right superficial femoral arteries, left 
common femoral arteries, and left superficial femoral arteries.To assess the evolution of 
plaques from baseline time to 24 months, patients were classified in three groups: no plaque 
(patients without plaque both at baseline and 24 months); de novo plaque (appearance of 
plaque at 24 months); and baseline plaque (plaques both at baseline and 24 months). 
Furthermore, a classification according the location of plaques was performed: any plaque 
(presence of plaque in any territorie); carotid plaque (presence of plaque in carotid territories 
exclusively????); and femoral plaque (presence of plaque in femoral territories 
exclusively????);. Patients were classified in three groups according to the number of territories 
with plaques: 0; 1 to 4; and ≥5. The increase in number of territories with plaques from baseline 
to 24 months was also determined. 
Vascular Doppler MD2 Hungleigth was used with an 8 MHz transducer and a sleeve for making 
manual blood pressure. The determination of blood pressure was performed in the brachial 
artery in both arms and in both feet. To calculate the ABI, the higher brachial blood pressure 
was used or the closest in time to the malleolar measure. A pathological ABI was defined as a 
value ≤0.9, diagnostic of a limb ischemia, or ≥1.4, diagnostic of arterial incompressibility and 
stiffness, usually ascribed to vascular wall calcification. 
AD was scored into 2 groups according to the ultrasonography findings and the ABI 
measurements: Stage 0-1 (AD 0-1), that included subjects with ABI ≥0.7 and/or carotid IMT 
≥90% according to reference range (RR), and Stage 2-3 (AD 2-3), that included patients with 
ABI <0.7 and/or carotid plaque without or with stenosis >50%.  
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1.4. Events 
Events were classified as cardiovascular events, cardiovascular mortality, non- cardiovascular 
mortality, and all-cause mortality (both cardiovascular and non- cardiovascular). Cardiovascular 
events included angina pectoris, acute myocardial infarction, ischemic stroke, cerebral 
infarction, subarachnoid hemorrhage, intracerebral hemorrhage, cardiac insufficiency, 
atherosclerosis of extremities with intermittent claudication and abdominal aortic aneurysm. 
Causes of cardiovascular mortality were defined as: myocardial ischemia and infarction, 
hyperkalemia or arrhythmia, cerebrovascular accident (ischemic or hemorrhagic), hemorrhage 
due to aneurysm rupture, mesenteric infarct and sudden death. Non- cardiovascular mortality 
causes included infection, neoplasia, accident, renal, uremic, non-determined or unknown 33.  
1.5. Statistical Analysis 
Normality of the continuous variables was assessed by normal probability plots. Variables were 
expressed as mean±SE. Continuous variables were evaluated by the ANOVA or the non-
parametric Mann-Whitney test. Bivariate correlations were calculated by the Spearman’s 
correlation coefficient. Multiple linear regression analyses, using the natural logarithmic 
transformation of baseline circulating ACE2 activity or the number of territories with plaques at 
24 months as dependent variables, were performed to identify independent predictors of these 
variables. These analyses were adjusted by age, gender and diabetes, which have been 
previously described as independent predictors of increased circulating ACE2 activity in CKD3-
5 patients 26.  SPSS version 18.0 for Windows was used for statistical calculations. P<0.05 was 
considered statistically significant. 
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2. Results 
2.1. ACE2 activity and  renal function  
Baseline circulating ACE2 activity was slightly increased in patients that doubled serum 
creatinine as compared with stable patients (55.66±9.58 RFU/μL/h versus 43.04±1.27, 
p=0.154). There were no differences between decrease in 50% of eGFR and baseline 
circulating ACE2 (52.17±6.86 versus 43.01±1.28, p=0.132). There were no differences in 
baseline circulating ACE2 between patients that needed renal replacement therapy (kidney 
transplant or dialysis) and patients that maintained kidney function (41.11±3.22 versus 
45.55±1.17, p=0.792 and 52.03±5.20 versus 44.75±1.13, p=0.446; respectively).  
2.2. ACE2 activity and atherosclerosis  
The relationship between baseline circulating ACE2 levels and subclinical atherosclerosis was 
studied. The association of baseline circulating ACE2 activity and evolution of plaques followed 
the same pattern in the any plaque (Figure 2A) and femoral plaque (Figure 2B) groups: patients 
with de novo plaque (any plaque: 41.97±2.44; femoral plaque: 46.62±3.19) and baseline plaque 
(any plaque: 48.14±1.71; femoral plaque: 48.85±1.90) showed higher levels of baseline 
circulating ACE2 activity as compared to patients with no plaque (any plaque: 34.04±1.55, 
p=0.007; femoral plaque: 35.89±1.50, p=0.002). In addition, levels of baseline ACE2 activity 
were significantly higher in patients with baseline plaque as compared to de novo plaque 
(p<0.001 for both any plaque and femoral plaque groups). For carotid plaque only a significant 
difference between no plaque and baseline plaque was found (38.37±1.32 versus 48.90±2.10, 
p<0.001) (Figure 2C). We also determined the levels of baseline circulating ACE2 activity 
according to the number of territories with plaques (maximum of 10 territories) at 24 months 
(Figure 2D). Patients with higher number of territories with plaques (1-4 and ≥5) had higher 
levels of baseline ACE2 activity (43.02±1.48 and 52.07±2.96, respectively) as compared to 
patients without plaque at 24 months (34.50±1.80, p<0.001 and p<0.001). Baseline ACE2 
activity in patients with ≥5 territories was significantly higher as compared to patients with 1-4 
territories (p=0.003). Furthermore, patients with an increase in the number of territories with 
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plaques at 24 months as compared to stable patients, showed significantly higher levels of 
baseline ACE2 activity (46.90±1.63 vs 38.73±1.59, p<0.001) (Figure 2E). 
We found a significant but weak correlation between baseline ACE2 activity and IMT at 24 
months (p=0.023). Furthermore, baseline circulating ACE2 activity was higher in patients with 
pathological ABI (defined as a value ≤0.9 or ≥1.4) as compared to patients with normal ABI 
(51.53±3.49 vs 42.13±1.20, p=0.002) (Figure 2F). Patients with severe AD (AD 2-3) showed 
increased levels of baseline circulating ACE2 activity as compared to those with incipient AD 
group (AD 0-1) (47.47±1.58 vs 35.74±1.83, p<0.001) (Figure 2G). 
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Figure 2. Association of plaques with baseline circulating ACE2 activity. A) Any Plaque. 
Baseline circulating ACE2 activity was significantly increased in patients with de novo plaque 
(p=0.009) and baseline plaque (p<0.001) as compared to those patients with no plaque. B) 
Femoral plaque. Patients with femoral de novo plaque (p=0.002) and baseline plaque 
(p<0.001) had elevated levels of baseline ACE2 activity as compared to those patients with no 
plaque. C) Carotid plaque. Baseline circulating ACE2 activity was significantly increased in 
patients with baseline plaque as compared to those patients without plaque (p<0.001). D) 
Number of territories with plaques at 24 months. Baseline circulating ACE2 activity was 
significantly increased in Patients with higher number of territories with plaques at 24 months (1-
4 and ≥5) (p=0.001 and p<0.001). Furthermore, patients with ≥5 territories had increased levels 
of baseline ACE2 activity as compared to patients with 1-4 territories with plaques (p=0.007). E) 
Increase in number of territories with plaques at 24 months. Patients were classified in two 
groups depending on whether they had increased the number of territories with plaques from 
baseline to 24 months or not. Baseline ACE2 activity was significantly elevated in patients that 
have increased the number of territories with plaques (p<0.001). F) Association of subclinical 
atherosclerosis with baseline circulating ACE2 activity: Pathological ABI at 24 months. 
Baseline circulating ACE2 activity was increased in patients with a pathological ABI at 24 
months of follow-up. G) Association of subclinical atherosclerosis with baseline circulating 
ACE2 activity: Atheromatous disease at 24 months. Baseline circulating ACE2 activity was 
increased in patients with severe AD (AD 2-3) at 24 months as compared to patients in incipient 
stages of AD (AD 0-1) (p<0.001). ABI: ankle-brachial index; AD: atheromatous disease.  
 
Clinical data according to the number of territories with plaques at 24 months or the increase in 
number of territories are shown in Table 1. Male gender, diabetes, hypertension, dyslipidemia, 
older age and smoking habits were significantly increased in patients with territories with 
plaques as compared to patients without plaques. In addition, circulating ACE2 activity was 
higher as the number of territories increased. The percentage of patients with family history of 
CVD was also increased in those patients with territories, but it did not reach statistical 
significance. There was no difference between renal parameters and the number of territories 
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with plaque (Table 1). Clinical data regarding the increase in number of territories during the 24 
months of follow-up showed the same pattern as mentioned above (Table 1). 
Table 1. Clinical parameters according to the number of territories with plaques or the increase 
in the number of territories with plaques. 
 Number of territories with plaques at 
24 months 
 
 0 1-4 ≥5 p-value 
Gender (% male) 44.6 60.0 77.7 <0.001 
Age (years) 47.1±13.7 60.5±9.5 65.6±7.5 <0.001 
Diabetes (%) 14.9 23.1 38.7 <0.001 
Hypertension (%) 86.2 93.2 96.8 <0.001 
Dyslipidemia (%) 59.5 69.7 75.5 0.001 
Family history of CVD (%) 9.2 10.6 7.7 0.388 
Smoking habits (%) 40.0 53.8 72.3 <0.001 
Doubling serum creatinine (%) 2.5 2.4 1.6 0.762 
50% decrease in eGFR (%) 4.4 3.4 2.8 0.695 
Baseline circulating ACE2 activity (RFU/μL/h) 34.5±25.1 43.0±33.1 52.1±52.1 <0.001 
 
Increase in number of territories  
with plaques 
 
 No Yes p-value 
Gender (% male) 56.7 66.3 0.002 
Age (years) 54.8±13.7 62.3±9.5 <0.001 
Diabetes (%) 18.0 31.4 <0.001 
Hypertension (%) 88.7 95.6 <0.001 
Dyslipidemia (%) 64.2 72.5 0.006 
Family history of CVD (%) 8.8 9.8 0.576 
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Smoking habits (%) 50.5 60.5 0.002 
Doubling serum creatinine (%) 1.6 2.7 0.301 
50% decrease in GFR (%) 3.5 3.5 0.975 
Baseline circulating ACE2 activity (RFU/μL/h) 38.7±31.3 46.9±39.6 0.001 
Values for categorical variables are given as percentage; values for continuous variable as 
mean ±SD. CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate. 
 
By multivariate linear regression analysis, with baseline circulating ACE2 activity as dependent 
variable and adjusting by age, gender and diabetes, pathological ABI and increased number of 
territories with plaques were independently associated with increased baseline circulating ACE2 
activity (Table 2). To further confirm baseline circulating ACE2 as a potential biomarker of 
atherosclerosis at 24 months of follow-up, a multivariate linear regression analysis was 
performed with the number of territories with plaques at 24 months as dependent variable. The 
analysis was adjusted by age, gender and diabetes. Male gender, older age, diabetes and 
increased baseline circulating ACE2 activity were independent predictors of atherosclerosis at 
24 months of follow-up (Table 2). 
 
 
Table 2. Multivariate linear regression analysis 
Model 1. Dependent variable: baseline circulating ACE2 activity (expressed in LnACE2) 
 Standardized 
coefficient (β) P-value 
Male 0.222 <0.001 
Age 0.002 0.953 
Diabetes 0.047 0.134 
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Pathological ABI at 24 months 0.066 0.038 
Number of territories with plaques 
at 24 months 0.111 0.003 
Model 2. Dependent variable: number of territories with plaques at 24 months of follow-
up 
 Standardized 
coefficient (β) P-value 
Male 0.193 <0.001 
Age 0.434 <0.001 
Diabetes 0.143 <0.001 
Baseline circulating ACE2 activity 0.094 0.001 
 
Model 1: multivariate linear regression analysis of potential predictors of baseline 
circulating ACE2 activity. By multiple linear regression, and adjusting by gender, age and 
diabetes, pathological ABI and number of territories with plaques at 24 months were found as 
potential predictors of increased baseline ACE2 activity (R=0.301). Model 2: multivariate 
linear regression analysis of potential predictors of territories with plaques at 24 months 
of follow-up. When multiple linear regression was performed with the number of territories with 
plaques as the dependent variable, and also adjusting by gender, age and diabetes, we found 
that increased baseline ACE2 activity still remained as a potential predictor of increased number 
of territories with plaques (R=0.559). 
Data are expressed as regression coefficients and P-value. Dependent variable in model 1: 
baseline circulating ACE2 activity (expressed in LnACE2). Dependent variable in model 2: 
number of territories with plaques at 24 months. Adjusted by gender, age and diabetes. 
ABI, ankle-brachial index.  
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2.3. ACE2 activity and cardiovascular and non-cardiovascular events  
No differences were found regarding baseline circulating ACE2 activity, cardiovascular events 
and cardiovascular mortality during the follow-up. Baseline circulating ACE2 was significantly 
higher in non-CV and all-cause of mortality patients (Table 3). 
Table 3. Association of events and mortality with baseline circulating ACE2 activity 
 
      Baseline circulating ACE2 
activity p-value 
Cardiovascular event 
No 45.40±1.16 
0.167 
Yes 43.63±3.33 
Cardiovascular mortality 
No 45.40±1.13 
0.705 Yes 38.88±4.90 
Non-Cardiovascular mortality 
No 44.80±1.12 
0.013 Yes 63.37±9.12 
All-cause mortality 
No 44.96±1.16 
0.023 
Yes 51.03±4.40 
 
Values are expressed as mean±SD 
 
3. Discussion 
In our study we analyze the association between baseline circulating ACE2 activity, silent 
atherosclerosis, renal function progression and cardiovascular events in a subpopulation of the 
NEFRONA study during 24 months of follow-up. We found that in non-dialysis CKD3-5 patients 
elevated baseline circulating ACE2 activity is associated with increased risk for silent 
atherosclerosis. In CKD3-5 patients, atheromatosis progression is associated with male gender, 
older age, diabetes and baseline circulating ACE2 activity. These results suggest that ACE2 
activity may serve as a biomarker to predict cardiovascular risk before CVD (angina pectoris, 
ischemic stroke or infarction) is established. 
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Studies in the NEFRONA population have been focused on the prevalence of silent 
atherosclerosis in CKD patients as compared to healthy population. It has been demonstrated 
that the prevalence of atheromatous plaques is increased in CKD population and that the 
highest prevalence is observed among dialysis patients12, 13, 34. As expected, the prevalence 
rates of severe carotid AD were more than two fold higher in patients with diabetic nephropathy 
as compared to those with any other causes of kidney disease. Moreover, the prevalence of 
silent AD increases with the severity of CKD, confirming previous findings in the whole cohort 12, 
35. Thus, patients with diabetes-induced renal disease are more likely to have endothelial 
damage beyond the kidneys. Patients with diabetic nephropathy at any grade of CKD are at 
particularly high risk of subclinical severe AD compared to any other causes of CKD. The use of 
carotid ultrasound can help in the early detection of AD, particularly in CKD population, in whom 
the classical risk scoring has been proven inefficacious. In addition, Martin et al. have also 
shown that high serum phosphate levels are associated with higher risk of atherosclerosis, 
expressed as the presence of plaques detected by ultrasound 36.  
Recently, atheromatosis progression has been assessed in the NEFRONA population during 24 
months of follow-up. They found four main findings: (1) a high prevalence of CKD patients with 
atheromatous plaque in carotid and/or femoral territories; (2) the only variables with a 
homogeneous association with the progression of plaque across CKD stages were the 
presence of diabetes and two interactions of age with ferritin and the presence of plaque at 
baseline; (3) risk factors predicting atheromatosis progression are different depending on the 
CKD stage; (4) and the progression of atheromatosis is associated with the progression of CKD. 
Consequently, they support the utility of the determination of atheroma plaque presence by 
arterial ultrasound as a powerful tool to predict atheromatosis progression in patients with CKD. 
Our study suggests that baseline ACE2 activity may predict 24-month atheromatosis 
progression measured by the increased number of territories with plaques in patients with non-
dialysis CKD.  
The RAS is a major hormonal system involved in the pathophysiology of CVD. ACE2 
counterbalances the vasoconstrictor adverse effects of AngII by converting it to Ang1-7 17. Thus, 
several studies have proposed ACE2 as an emergent biomarker for CVD and it may become a 
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therapeutic target for atherosclerotic lesions. Initial studies in a large cohort were able to detect 
circulating ACE2 activity only in patients with CVD19. Subsequently studies demonstrated that 
circulating ACE2 activity can be detected both in patients with CVD and in healthy subjects20 
and that it was increased in heart failure patients21, 37. In concordance, we have shown that 
ACE2 activity is up-regulated in the acute phase of ST-elevation myocardial infarction and that it 
correlates with the infarct size22. Furthermore, in kidney transplant patients with previous history 
of ischemic heart disease we have observed that circulating ACE2 activity was increased24. In 
experimental studies, circulating and renal cortex ACE2 is increased in diabetic mice, 
suggesting a potential mechanism to adapt to diabetes-associated Ang II overactivity38. In 
addition, a cumulative damage from Ang II, that caused an age-dependent cardiomyopathy, 
was observed in mice with deletion of ACE239. Therefore, circulating ACE2 activity may serve 
as a biomarker for CV risk. In agreement with these previous findings our results now suggest 
that circulating ACE2 activity may be a surrogate marker of CV risk by predicting the silent 
atheromatosis disease. 
Soro-Paavonen et al. determined that ACE2 activity was increased in patients with diabetes, 
vascular complications and decreased eGFR23. In dialysis patients, males had increased levels 
of circulating ACE2 activity as compared to females25. In agreement, we have also previously 
demonstrated that ACE2 activity is increased in CKD males as compared to females. In CKD3-5 
patients baseline circulating ACE2 activity correlated with the classical cardiovascular risk 
factors, such as male gender, advanced age and diabetes, while in dialysis patients it correlated 
with male gender and advanced age26. In experimental studies circulating ACE2 has been 
shown to be increased in diabetic mice. This increase was blunted by the administration of 
insulin (and glucose levels normalization) and the administration of vitamin D analog (without 
changes in glucose levels)32, 38. Giving these results one may surmise that the increase in 
circulating ACE2 activity may be an indicator of increased risk of CVD. Certain therapies aimed 
to decrease cardiovascular risk appear to modify circulating ACE2 activity. 
Zulli et al. described that ACE2 was present on the endothelial cell layer overlying neo-intima 
and atherosclerotic lesions from thoracic aorta in rabbits. Specifically, they identified that a high 
proportion of macrophages and smooth muscle actin-positive cells within atherosclerotic 
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plaques expressed ACE240. In concordance with these findings, ACE2 is also expressed in 
human atherosclerotic plaques and located in different cell types present in the lesion, such as 
endothelial cells and macrophages41. Early atherosclerotic lesions have been described to 
involve endothelial cell dysfunction, vascular smooth muscle cells (VSMC) proliferation and 
migration and endothelial cell matrix deposition27. Several experimental studies, including 
animal models and endothelial and VSMC, have shown that ACE2 activation improves 
endothelial repair and regeneration and, as a consequence, reduces atherosclerosis27, 42. In 
addition, it has been described that inhibition of AngII-induced inflammation by ACE2 
overexpression may decrease endothelial dysfunction and, therefore, inhibit early 
atherosclerotic lesions28 and enhance stability of atherosclerotic plaques29. In our study, we 
demonstrated that an increase of the number of territories with plaques at 24 months of follow-
up is independently associated with elevated baseline circulating ACE2 activity in CKD3-5 
patients. Thus, increased circulating ACE2 may activate circulating mechanisms that will lead to 
plaque formation and progression. 
 We also studied if circulating ACE2 activity at baseline may serve as a potential predictor of CV 
events and mortality over 2-years of follow-up in CKD3-5 patients. Surprisingly, we did not find 
differences between baseline ACE2 activity and cardiovascular events or cardiovascular 
mortality. We ascribe the lack of differences to the short-term follow-up and to the low number of 
cardiovascular events observed during the 24 months of follow-up in patients without previous 
history of CVD. Therefore, we surmise that a longer term follow-up will help us to better 
elucidate the role of ACE2 as a biomarker of CVD in our study population. There are no 
previous studies that have explored the association between circulating ACE2 activity and renal 
function progression. We did not find any significant difference in patients that doubled serum 
creatinine or had a 50% decrease in eGFR at 24 months of follow-up versus stable patients. 
Again, the lacking of significant differences may be related to the low number of patients with 
renal endpoints (doubling serum creatinine and/or 50% decrease in eGFR) and to the short-
term follow up. 
In conclusion, our study shows that baseline ACE2 activity may serve as a potential predictor 
for the development of silent atheromatosis in CKD patients without previous history of CV 
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disease. The strength of this association and the potential of baseline circulating ACE2 for 
predicting future cardiovascular events and mortality need longer follow-up studies. 
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Polanco (Teruel); Bover Sanjuan, Jordi. Fundació Puigvert. IIB Sant Pau (Barcelona); Bronsoms Artero, 
Josep. Clínica Girona (Girona); Cabezuelo Romero, Juan B; Muray Cases, Salomé. Hospital Reina Sofía 
(Murcia); Calviño Varela, Jesús. Hospital Universitario Lugus Augusti (Lugo); Caro Acevedo, Pilar. Clínica 
Ruber (Madrid); Carreras Bassa, Jordi. Diaverum Baix Llobregat (Barcelona); Cases Amenós, Aleix; Massó 
Jiménez, Elisabet. Hospital Clínic (Barcelona); Castilla Pérez, Jesús. Hospital de la Defensa (Zaragoza); 
Cigarrán Guldris, Secundino; López Prieto, Saray. Hospital Da Costa (Lugo); Comas Mongay, Lourdes. 
Hospital General de Vic (Barcelona); Comerma, Isabel. Hospital General de Manresa (Barcelona); 
Compte Jové, Mª Teresa, Hospital Santa Creu Jesús (Tarragona); Cuberes Izquierdo, Marta. Hospital 
Reina Sofía (Navarra); de Álvaro, Fernando; Hevia Ojanguren, Covadonga. Hospital Infanta Sofía 
(Madrid); de Arriba de la Fuente, Gabriel. Hospital Universitario Guadalajara (Guadalajara); del Pino y 
Pino, Mª Dolores. Complejo Hospitalario Universitario Torrecardenas (Almería); Diaz-Tejeiro Izquierdo, 
Rafael. Hospital Virgen de la Salud (Toledo); Dotori, Marta. USP Marbella (Málaga); Duarte, Verónica. 
Hospital de Terrassa (Barcelona); Estupiñan Torres, Sara. Hospital Universitario Canarias (Santa Cruz de 
Tenerife); Fernández Reyes, Mª José. Hospital de Segovia (Segovia); Fernández Rodríguez, Mª Loreto. 
Hospital Príncipe de Asturias (Madrid); Fernández, Guillermina. Clínica Santa Isabel (Sevilla); Galán 
Serrano, Antonio. Hospital General Universitario de Valencia (Valencia); García Cantón, Cesar. Hospital 
Universitario Insular de Gran Canaria (Las Palmas); García Herrera, Antonio L. Hospital Universitario 
Puerto Real (Cádiz); García Mena, Mercedes. Hospital San Juan de Dios (Zaragoza); Gil Sacaluga, Luis; 
Aguilar, Maria. Hospital Virgen del Rocío (Sevilla); Górriz, José Luis. Hospital Universitario Doctor Peset 
(Valencia); Huarte Loza, Emma. Hospital San Pedro (Logroño); Lerma, José Luis. Hospital Universitario 
Salamanca (Salamanca); Liebana Cañada, Antonio. Hospital de Jaén (Jaén); Marín Álvarez, Jesús Pedro. 
Hospital San Pedro de Alcántara (Cáceres); Martín Alemany, Nàdia. Hospital Josep Trueta (Girona); 
Martín García, Jesús. Hospital Nuestra Señora de Sonsoles (Ávila); Martínez Castelao, Alberto. Hospital 
Universitari de Bellvitge (Barcelona); Martínez Villaescusa, María. Complejo Hospitalario Universitario de 
Albacete (Albacete); Martínez, Isabel. Hospital Galdakao (Bilbao); Moina Eguren, Iñigo. Hospital Basurto 
(Bilbao); Moreno Los Huertos, Silvia. Hospital Santa Bárbara (Soria); Mouzo Mirco, Ricardo. Hospital El 
Bierzo, Ponferrada (León); Munar Vila, Antonia. Hospital Universitari Son Espases (Palma de Mallorca); 
Muñoz Díaz, Ana Beatriz. Hospital Virgen del Consuelo (Valencia); Navarro González, Juan F. Hospital 
Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife); Nieto, Javier; Carreño, Agustín. 
Hospital General Universitario de Ciudad Real (Ciudad Real); Novoa Fernández, Enrique. Complexo 
Hospitalario de Ourense (Ourense); Ortiz, Alberto; Fernandez, Beatriz. IIS-Fundación Jiménez Díaz 
(Madrid); Paraíso, Vicente. Hospital Universitario del Henares (Madrid); Pérez Fontán, Miguel. Complejo 
Hospitalario Universitario A Coruña (A Coruña); Peris Domingo, Ana. Hospital Francesc de Borja 
(Valencia); Piñera Haces, Celestino. Hospital Universitario Marqués de Valdecilla (Santander); Prados 
Garrido, Mª Dolores. Hospital Universitario San Cecilio (Granada); Prieto Velasco, Mario. Hospital de 
León (León); Puig Marí, Carmina. Hospital d'Igualada (Barcelona); Rivera Gorrín, Maite. Hospital 
Universitario Ramón y Cajal (Madrid); Rubio, Esther. Hospital Puerta del Hierro (Madrid); Ruiz, Pilar. 
Hospital Sant Joan Despí Moisès Broggi (Barcelona); Salgueira Lazo, Mercedes; Martínez Puerto, Ana 
Isabel. Hospital Virgen Macarena (Sevilla); Sánchez Tomero, José Antonio. Hospital Universitario de la 
Princesa (Madrid); Sánchez, José Emilio. Hospital Universitario Central de Asturias (Oviedo); Sans 
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Lorman, Ramon. Hospital de Figueres (Girona); Saracho, Ramon. Hospital de Santiago (Vitoria); Sarrias, 
Maria; Prat, Oreto. Hospital Universitari Vall d’Hebron (Barcelona); Soler, María José; Barrios, Clara. 
Hospital del Mar (Barcelona); Sousa, Fernando. Hospital Rio Carrión (Palencia); Toran, Daniel. Hospital 
General de Jerez (Cadiz); Tornero Molina, Fernando. Hospital de Sureste (Arganda del Rey); Usón 
Carrasco, José Javier. Hospital Virgen de la Luz (Cuenca); Valera Cortes, Ildefonso. Hospital Virgen de la 
Victoria (Málaga); Vilaprinyo del Perugia, Mª Merce. Institut Catala d’Urologia i Nefrologia (Barcelona); 
Virto Ruiz, Rafael C. Hospital San Jorge (Huesca). 
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